Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

European Journal of Pharmacology

Volumn 630, Issue 1-3, 2010, Pages 158-162

  McClean, Paula L ^a   Gault, Victor A ^a   Harriott, Patrick ^b   Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Hippocampus; Incretins; Liraglutide; LTP; Neurodegeneration; Neurotransmission

Indexed keywords

AMYLOID BETA PROTEIN; EXENDIN[9-39] AMIDE; GLUCAGON LIKE PEPTIDE 1 [7 ASPARTIC ACID]; GLUCAGON LIKE PEPTIDE 1 [9 PROLINE]; GLUCAGON LIKE PEPTIDE 1 [N GLYCINE]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; GLYCEMIC CONTROL; HIPPOCAMPUS; INSULIN RELEASE; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; LONG-TERM POTENTIATION; MALE; RATS; RATS, WISTAR; SYNAPSES;

EID: 77649187436     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.12.023     Document Type: Article

References (53)

1. Acuna-Goycolea C., van den Pol A. Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. J. Neurosci. 2004, 24:8141-8152.
2. Biessels G.J., De Leeuw F.E., Lindeboom J., Barkhof F., Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatry 2006, 77:304-307.
3. Biswas S.C., Buteau J., Greene L.A. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem. Res. 2008, 33:1845-1851.
4. Buse J.B., Rosenstock J.R., Sesti G., Schmidt W.E., Montanya E., Brett J.H., Zychma M., Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009, electronic publication ahead of print.
5. Carro E., Torres-Aleman I. Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects?. Expert Rev. Neurother. 2004, 4:79-86.
6. Carro E., Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:127-133.
7. Collingridge G.L., Bliss T.V.P. NMDA receptors - their role in long-term potentiation. Trends Neurosci. 1987, 10:288-293.
8. Courreges J.P., Vilsboll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Verhoeven R., Buganova I., Madsbad S. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 2008, 25:1129-1131.
9. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:3434-3438.
10. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9:1173-1179.
11. Flatt P.R., Bailey C.J., Green B.D. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr. Drug Metab. 2009, 10:125-137.
12. Gault V.A., Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharmacol. 2008, 587:112-117.
13. Gault V.A., Holscher C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by Beta-amyloid. J. Neurophysiol. 2008, 99:1590-1595.
14. Gault V.A., Flatt P.R., O'Harte F.P. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun. 2003, 308:207-213.
15. Gengler S., Gault V., Jucker M., Holscher C. Val(8)GLP-1, a protease-resistant incretin analogue, prevents the impairment of hippocampal synaptic plasticity in an APP/PS-1 mouse model of Alzheimer's disease. Annual Soc Neurosci meeting, Washington DC 2008, 740. 716.
16. Gengler S., Gault V., Harriott P., Hölscher C. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp. Brain Res. 2007, 179:621-630.
17. Gilman C.P., Perry T., Furukawa K., Grieg N.H., Egan J.M., Mattson M.P. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J. Neurochem. 2003, 87:1137-1144.
18. Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best. Pract. Res. Clin. Endocrinol. Metab. 2007, 21:497-516.
19. Green B.D., Gault V.A., Flatt P.R., Harriott P., Greer B., O'Harte F.P. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch. Biochem. Biophys. 2004, 428:136-143.
20. Green B.D., Gault V.A., O'Harte F.P., Flatt P.R. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Diabetes Obes. Metab. 2005, 7:595-604.
21. Hamilton A., Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 2009, 20:1161-1166.
22. Long-term Potentiation Induced by Stimulation on the Positive Phase of Theta Rhythm: A Better Model for Learning and Memory? 2001, Cambridge University Press, Cambridge. C. Hölscher (Ed.).
23. Hölscher C., Anwyl R., Rowan M.J. Stimulation on the positive phase of hippocampal theta rhythm induces long-term potentiation which can be depotentiated by stimulation on the negative phase in area CA1 in vivo. J. Neurosci. 1997, 17:6470-6477.
24. Wheeler D.B., Randall A., Tsien R.W. Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission. Science 1994, 264:107-111.
25. Hölscher C., Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's Disease?. Neurobiol. Aging 2008, electronic publication ahead of print.
26. Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 2009, 45:101-113.
27. Hölscher C., Gengler S., Gault V., Harriott P., Mallot H. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur. J. Pharmacol. 2007, 561:85-90.
28. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 2004, 490:115-125.
29. Irwin N., Clarke G.C., Green B.D., Greer B., Harriott P., Gault V.A., O'Harte F.P., Flatt P.R. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem. Pharmacol. 2006, 72:719-728.
30. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27:313-318.
31. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
32. Leech C., Habener J. Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin. J. Biol. Chem. 1997, 272:17987-17993.
33. Li L., Hölscher C. Common pathological processes in Alzheimer Disease and Type 2 Diabetes: a review. Brain Res. Rev. 2007, 56:384-402.
34. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5(5):262-269.
35. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
36. McClean P., Fung K., McCurtin R., Gault V., Hölscher C. Novel GLP-1 analogues cross the blood brain barrier: a link between diabetes and Alzheimer's disease. Society for Neuroscience meeting, Chicago 2009, 529. 8.
37. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur. J. Endocrinol. 2009, 160:909-917.
38. Mora F., Exposito I., Sanz B., Blazquez E. Selective release of glutamine and glutamic acid produced by perfusion of GLP-1 (7-36) amide in the basal ganglia of the conscious rat. Brain Res. Bull. 1992, 29:359-361.
39. Oka J.I., Goto N., Kameyama T. Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus. Neuroreport 1999, 10:1643-1646.
40. Okamoto N., Hore S., Akazawa C., Hayashi Y., Shigemoto R., Mizuno N., Nakanishi S. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J. Biol. Chem. 1994, 269:1231-1236.
41. Perry T.A., Greig N.H. A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 2004, 5:565-571.
42. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302:881-888.
43. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 2002, 300:958-966.
44. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
45. Qin Z., Sun Z., Huang J., Hu Y., Wu Z., Mei B. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci. Lett. 2008, 444:217-221.
46. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
47. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 2004, 82:510-529.
48. Sarkar S., Fekete C., Legradi G., Lechan R.M. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 2003, 985:163-168.
49. Steen E., Terry B.M., Rivera E., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
50. Suzuki M., Fujikura K., Inagaki N., Seino S., Takata K. Localization of the ATP-sensitive K+channel subunit Kir6.2 in mouse pancreas. Diabetes 1997, 46:1440-1444.
51. Tomillero A., Moral M.A. Gateways to clinical trials Methods Find. Exp. Clin. Pharmacol. 2009, 31:47-57.
52. Winder D.G., Conn P.J. Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. J. Neurosci. 1993, 13:38-44.
53. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.